Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
| ▸ | SLC9A1 | P19634 | 5/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 7/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7919380 | 0.85 | SLC9A1 (0.48) | SLC9A1HTR5A | |
| SCHEMBL16502594 | 0.84 | CYP11B1 (0.49) | MKNK1MKNK2CYP11B1CYP11B2CYP17A1 | |
| SCHEMBL7920221 | 0.84 | MKNK1 (0.46) | MKNK1MKNK2SLC9A1HTR5A | |
| SCHEMBL16502773 | 0.84 | HTR5A (0.48) | SLC9A1HTR5A | |
| SCHEMBL16502585 | 0.83 | CYP11B1 (0.50) | MKNK1MKNK2CYP11B1CYP11B2CYP17A1 | |
| SCHEMBL7915997 | 0.82 | SLC9A1 (0.48) | MKNK1MKNK2SLC9A1CYP11B1HTR5A | |
| SCHEMBL7918322 | 0.82 | MKNK1 (0.49) | MKNK1MKNK2SLC9A1CYP3A4HTR5A | |
| SCHEMBL16502788 | 0.79 | SLC9A1 (0.50) | SLC9A1HTR5A | |
| SCHEMBL16502781 | 0.79 | HTR5A (0.48) | MKNK1MKNK2SLC9A1HTR5A | |
| SCHEMBL7919750 | 0.79 | HTR5A (0.43) | SLC9A1HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| EP-2394987-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090304-A1 | ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | HTR5A, HTR2A, HTR1A | MKNK1 4067/4885MKNK2 3819/4885SLC9A1 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.